Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 5,030 |
|
|||||
| News | - | ||||||
| Day High | 1.965 | Low High |
|||||
| Day Low | 1.95 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aeterna Zentaris Inc | AEZS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0066 | -0.34% | 1.95 | 17:16:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.965 | 1.95 | 1.965 | 1.95 | 1.9566 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 30 | 5,030 | $ 1.96 | $ 9,856 | - | 1.3601 - 3.38 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 200 | $ 1.95 | USD |
Aeterna Zentaris Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 9.47M | 4.86M | - | 4.5M | -16.55M | -3.41 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aeterna Zentaris News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AEZS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.04 | 2.07 | 1.95 | 1.96 | 10,859 | -0.09 | -4.41% |
| 1 Month | 1.96 | 2.26 | 1.95 | 2.06 | 13,991 | -0.01 | -0.51% |
| 3 Months | 1.90 | 2.39 | 1.68 | 1.99 | 16,463 | 0.05 | 2.63% |
| 6 Months | 1.73 | 2.51 | 1.3601 | 1.97 | 15,235 | 0.22 | 12.72% |
| 1 Year | 3.08 | 3.38 | 1.3601 | 2.30 | 12,687 | -1.13 | -36.69% |
| 3 Years | 0.8595 | 5.90 | 0.1645 | 0.6986656 | 631,677 | 1.09 | 126.88% |
| 5 Years | 4.25 | 5.90 | 0.1645 | 1.14 | 1,851,014 | -2.30 | -54.12% |
Aeterna Zentaris Description
| AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. |
